Serena Williams is opening up about her fitness journey, revealing that she uses the injectable GLP-1 weight loss drug ...

Serena Williams reveals her use of GLP-1, Zepbound and calls out the stigma surrounding the use of the popular weight loss drug.

Serena Williams is getting real about her weight-loss journey. Since April, the retired tennis legend has been on a GLP-1 ...

Williams, 43, in a new series of interviews, is revealing that GLP-1s are responsible for a recent 31-pound slim down. "I was on and off (the medication) and now completely on," she told ...

Serena Williams finally comes clean about her drastic weight change. She shares she lost 31 pounds through weight loss ...

For reasons that remain unclear, kidney cancer risk was higher in users of GLP-1 agonists, particularly those under 65 and those who were overweight versus obese.< Patients taking GLP-1 agonists for ...

Serena Williams has been taking a GLP-1 medication to help with her recent weight loss, she revealed for the first time in an exclusive TODAY interview.

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing cancer risk among patients with obesity, particularly for endometrial, ovarian, and meningioma cancers.

Columnist Teri Sforza writes that studies have found that semaglutide reduced alcohol intake, binge drinking and relapse ...

Sara H. Jodka of Dickinson Wright PLLC discusses the legal landscape surrounding GLP-1 programs for weight loss, in light of ...

GLP-1 receptor agonists may outperform metformin in lowering the risk for dementia, particularly Alzheimer’s disease and other nonvascular types, in patients with type 2 diabetes.

Older adults with diabetes using GLP-1 receptor agonist medications may face increased risk of serious eye conditions, study ...